[Botulinum toxin in adult patients with overactive bladder]
Mengarelli C, Augustovski F, Colaci C, Alfie V, García Martí S, Bardach A, Ciapponi A, Alcaraz A, Pichon-Riviere A
Record ID 32018004393
Spanish
Original Title:
Toxina botulínica en pacientes adultos con vejiga hiperactiva
Authors' recommendations:
Moderate-quality evidence shows that the use of botulinum toxin (Onabotulinumtoxin toxin A) in adult patients with overactive bladder as third-line therapy is likely to result in a significant net benefit in reducing the rates of urinary incontinence and nocturia at short term, when compared with placebo. Low-quality evidence suggests that in adult patients with overactive bladder who received treatment with botulinum toxin as third-line therapy, after pelvic floor muscle training and muscarinic drugs, could not show benefits when compared with nerve stimulation. This is because it did not show reduction of urinary incontinence episodes and urinary frequency, but it did show higher rates of adverse events such as urinary tract infections. Low-quality evidence suggests that in adult patients with overactive bladder treated with botulinum toxin as third-line therapy did not show differences in improvement of clinical symptoms when compared with posterior tibial nerve stimulation. The United States, United Kingdom and European Clinical Practice Guidelines and coverage policies recommend the use of Onabotulinum toxin Type A as an alternative, among thirdline therapies, in patients with overactive bladder refractory to first and second line therapies. Cost-effectiveness study reviews considered that, at short term, sacral nerve stimulation is the least cost-effective treatment when compared with botulinum toxin injection and posterior tibial nerve stimulation, at short term.
Details
Project Status:
Completed
Year Published:
2021
URL for published report:
https://www.iecs.org.ar/publicacion/?id=21613
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Argentina
MeSH Terms
- Urinary Bladder, Overactive
- Urinary Incontinence
- Botulinum Toxins
- Adult
- Botulinum Toxins, Type A
Contact
Organisation Name:
Institute for Clinical Effectiveness and Health Policy
Contact Address:
Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name:
info@iecs.org.ar
Contact Email:
info@iecs.org.ar
Copyright:
Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.